Swati Shukla1, Arpna Srivastava1, Sunil Kumar1, Usha Singh1, Sandeep Goswami1, Bhavna Chawla2, Mandeep Singh Bajaj2, Seema Kashyap3, Jasbir Kaur1. 1. Department of Ocular Biochemistry, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. 2. Oculoplasty & Pediatric Opthalmology Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. 3. Department of Ocular Pathology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India.
Abstract
AIM: To elucidate the mechanism of multidrug resistance in retinoblastoma, and to acquire more insights into in vivo drug resistance. METHODS: Three anticancer drug resistant Y79 human RB cells were generated against vincristine, etoposide or carboplatin, which are used for conventional chemotherapy in RB. Primary cultures from enucleated eyes after chemotherapy (PCNC) were also prepared. Their chemosensitivity to chemotherapeutic agents (vincristine, etoposide and carboplatin) were measured using MTT assay. Western blot analysis was performed to evaluate the expression of p53, Bcl-2 and various multidrug resistant proteins in retinoblastoma cells. RESULTS: Following exposure to chemotherapeutic drugs, PCNC showed less sensitivity to drugs. No significant changes observed in the p53 expression, whereas Bcl-2 expression was found to be increased in the drug resistant cells as well as in PCNC. Increased expression of P-glycoprotein (P-gp) was observed in drug resistant Y79 cells; however there was no significant change in the expression of P-gp found between primary cultures of primarily enucleated eyes and PCNC. Multidrug resistance protein 1 (Mrp-1) expression was found to be elevated in the drug resistant Y79 cells as well as in PCNC. No significant change in the expression of lung resistance associated protein (Lrp) was observed in the drug resistant Y79 cells as well as in PCNC. CONCLUSION: Our results suggest that multidrug resistant proteins are intrinsically present in retinoblastoma which causes treatment failure in managing retinoblastoma with chemotherapy.
AIM: To elucidate the mechanism of multidrug resistance in retinoblastoma, and to acquire more insights into in vivo drug resistance. METHODS: Three anticancer drug resistant Y79 human RB cells were generated against vincristine, etoposide or carboplatin, which are used for conventional chemotherapy in RB. Primary cultures from enucleated eyes after chemotherapy (PCNC) were also prepared. Their chemosensitivity to chemotherapeutic agents (vincristine, etoposide and carboplatin) were measured using MTT assay. Western blot analysis was performed to evaluate the expression of p53, Bcl-2 and various multidrug resistant proteins in retinoblastoma cells. RESULTS: Following exposure to chemotherapeutic drugs, PCNC showed less sensitivity to drugs. No significant changes observed in the p53 expression, whereas Bcl-2 expression was found to be increased in the drug resistant cells as well as in PCNC. Increased expression of P-glycoprotein (P-gp) was observed in drug resistant Y79 cells; however there was no significant change in the expression of P-gp found between primary cultures of primarily enucleated eyes and PCNC. Multidrug resistance protein 1 (Mrp-1) expression was found to be elevated in the drug resistant Y79 cells as well as in PCNC. No significant change in the expression of lung resistance associated protein (Lrp) was observed in the drug resistant Y79 cells as well as in PCNC. CONCLUSION: Our results suggest that multidrug resistant proteins are intrinsically present in retinoblastoma which causes treatment failure in managing retinoblastoma with chemotherapy.
Authors: M Filipits; J Drach; G Pohl; J Schuster; T Stranzl; J Ackermann; R Königsberg; H Kaufmann; H Gisslinger; H Huber; H Ludwig; R Pirker Journal: Clin Cancer Res Date: 1999-09 Impact factor: 12.531
Authors: Annemarie Larkin; Lorraine O'Driscoll; Susan Kennedy; Rachel Purcell; Elizabeth Moran; John Crown; Michael Parkinson; Martin Clynes Journal: Int J Cancer Date: 2004-11-01 Impact factor: 7.396
Authors: S Roy; E Kenny; S Kennedy; A Larkin; J Ballot; M Perez De Villarreal; J Crown; L O'Driscoll Journal: Anticancer Res Date: 2007 May-Jun Impact factor: 2.480
Authors: Carlos Rodriguez-Galindo; Matthew W Wilson; Barrett G Haik; Thomas E Merchant; Catherine A Billups; Nirali Shah; Alvida Cain; James Langston; Mindy Lipson; Larry E Kun; Charles B Pratt Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Revu V L Narayana; Pritikana Jana; Neha Tomar; Varsha Prabhu; Rohini M Nair; Radhika Manukonda; Swathi Kaliki; Sarah E Coupland; Jodi Alexander; Helen Kalirai; Anand K Kondapi; Geeta K Vemuganti Journal: Invest Ophthalmol Vis Sci Date: 2021-11-01 Impact factor: 4.799